Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

A Novel Drug Delivery System Design for Meloxicam

  • Kim, Hyun-Jo (Product Development & Planning, Kolon Pharm. Inc.) ;
  • Lee, Il-Kyu (R&D Center, Daejun Research Complex)
  • Published : 2005.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

A drug delivery system(DDS) for practically insoluble meloxicam was developed and evaluated by dissolution study. A novel DDS is two layered system, where the first layer is consisted of gas-forming agent for an immediate release and the second layer is composed of metolose SR(HPMC) for sustained release. This bilayered tablets were manufactured by using manual single punch machine. The results of dissolution study showed an initial burst release followed by sustained release for the experimental period time. From a pharmaceutical point of view, the designed DDS for meloxicam would be informative system in terms of poorly soluble analgesic medicines.

Keywords

References

  1. S. Gupta and L.-J. Crofford, An Update on specific COX-2 inhibitors: The COXIBs, Bulletin on the Rheumatic Disease., 50(1), 5245-5248 (2001)
  2. Rxlist, Mobic, Meloxicam, Pharmacology & Clinical review, US medicinal information
  3. M. Pairet, J. van Ryn, H. Schierok, A Mauz, G. Trummlitz and G. Engelhardt, Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. lnflamm Res., 47(6), 270-276 (1998) https://doi.org/10.1007/s000110050329
  4. E-M. Andreas, K.-D. Christine, H. Nina, H. Stefan, S. Jens and K.-H. Juergen, Water-so;uble meloxicam granulates, PCT W02004037264
  5. K. Laura, P. John, C.-R. Eugene and R. Tuula, Nanoparticulate meloxicam formulations, US patent US2004229038
  6. S. Baroota, S.-P. Agarwal, Meloxicam complexation with ${\beta}$-cyclodextrin: influence on the anti-inflammatory and ulcerogenic activity, 58, 73-74 (2003)
  7. N.-B. Naidu, K.P.R. Chowdary, K.Y.R. Murthy, Y. Satyanarayana, A.-R. Hayman and G. Heeket, Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems, Journal of Pharmaceutical and Biomedical Analysis, 35, 75-86 (2004) https://doi.org/10.1016/j.jpba.2004.01.003
  8. R. Banerjee, H. Chakraborty and M. Sarkar, Host-Guest complexation of oxicam NSAIDs with ${\beta}$-cyclodextrin, Biopolymers, 75(4), 355-365 (2004) https://doi.org/10.1002/bip.20147
  9. M.-M. Ghorab, H.-M. Abdel-Salam, M.-A EI-Sayad and M.-M. Mekhel, Tablet formulation containing meloxicam and beta-cyclodextrin: Mechanical characterization and bioavailability evaluation, AAPS Pharm. Sci. Tech., 27(5) , e59 (2004)
  10. J. Dequeker, and F. degner, Inflammation Research Editorial, lnflamm. Res., 50, Supplement 1 S3-S4 (2001)
  11. E.-M. Lemmel, W. Bolten, R. Burgos-Vargns, P. Platt, M. Nissila, D. Sahlberg, et al., Efficacy and safety of meloxicam in patients with rheumatoid arthritis, J. Rheumatopl., 24, 282-290 (1997)
  12. B. Lund, M. Dialel, R. Bluhmki and A double-blind, randomized placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J. Rheumatol, 27, 32-37 (1998) https://doi.org/10.1080/030097498441146
  13. D. Vocum, D. Hall, and P. Ruszko, Meloxicam osteoarthritis team. Efficacy and safety of meloxicam in the treatment of osteoarthritis. Arthr Rheum., 42(Suppl), S147 (1999)
  14. M. Dougados, A. Gueguen, J.-P. Nakache, I. Veys, E.-M. Zeildler, et a!., Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks nonsteroidal anti-inflammatory drug trial. Rheumatology, 38, 235-244 (1999) https://doi.org/10.1093/rheumatology/38.3.235
  15. D. Duchene, D. Wouessidiewe, Pharmaceutical uses of cyclodextrins and derivatives, Drug Dev. lnd. Pharm., 16, 2487-2499 (1990) https://doi.org/10.3109/03639049009058543
  16. O. Berkers, E.Y. Uijioridal, J.-H. Haijnen, A. Bult and W.-J. Underberg, Cyclodextrins in the pharmaceutical field. Drug Dev. lnd. Pharm. 17, 1503-1549 (1991) https://doi.org/10.3109/03639049109026630
  17. Ludipress, Technical information, BASF Chem. Co., Supersedes issue of October 2001, September, 2003
  18. Metolose SR (Hypromellose), Technical note, ShinEtsu Chem. Co., issued on October, 2002
  19. D.-X. Zhejiang, B. Xue and Y.-X. Ban. Investigation on release model of insoluble drug in hydroxypropyl methycellulose matrix tablets, 33(3), 225-228 (2004)
  20. B. Pose-Vilamovo, C. Rodriguez-Tenreiro, J.-F. Rosa dos Santos, J. Vazquez-Doval, A. Concheiro, C. Alvarez-Lorenzo and J.-J. Torres-Labandeira, Modulating drug release with cyclodextrins in hydroxypropyl methylcellulose gels and tablets. J. Control Release. 10;94(2-3), 351-363 (2004)
  21. R.-O. Williams 3rd, M.-A .Sykora and V. Mahaguna, Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets. AAPS Pharm. Sci. Tech. Jun, 9;2(2):E8 (2001)